FDAsafety guidance66% confidence
S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Merz Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · Botulinum Toxin
- Sub-indication
- General
Related signal: FDA Accepts Supplement for Xeomin (incobotulinumtoxinA) by Merz Pharmaceuticals